Mirati Therapeutics Inc expected to post a loss of $2.84 a share - Earnings Preview

Mirati Therapeutics

03/11/2023 12:34

* Mirati Therapeutics Inc  MRTX.OQ   MRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The San Diego California-based  company is expected to
report  a
242.4% increase in revenue to $18.598 million from $5.43 million
a year ago, according to the mean estimate from 14 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Mirati Therapeutics
Inc
is for a loss of $2.84 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 11
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mirati
Therapeutics Inc is $60​, above​ its last closing price
of $55.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -3.15       -3.17      -3.04     Beat    4.1
 Mar. 31 2023  -3.56       -3.55      -3.18     Beat    10.5
 Dec. 31 2022  -3.41       -3.55      -3.51     Beat    1.2​
 Sep. 30 2022  -3.48       -3.48      -3.09     Beat    11.1
 ​​Jun.        -3.47       -3.49      -3.18     Beat    8.8
 30 2022                                                
 Mar. 31 2022  -3.51       -3.49      -3.40     Beat    2.5​
 Dec. 31 2021  -2.90       -3.00      -3.72     Missed  -23.8
 Sep. 30 2021  -3.03       -2.89      -1.55     Beat    46.3
 This summary was machine generated November 3 at 12:34 GMT.  All
figures in US dollars  unless otherwise stated